Thryv Therapeutics to Sponsor 2024 SADS Foundation Conference
04 Nov 2024 //
PR NEWSWIRE
Thryv Therapeutics Reports Top-Line Results In Long QT Syndrome
15 Oct 2024 //
PR NEWSWIRE
Thryv Therapeutics Gets FDA Orphan Drug Designation for LQT-1213
01 Oct 2024 //
PR NEWSWIRE
Thryv Therapeutics - 2023 Year End Report
19 Dec 2023 //
PR NEWSWIRE
Thryv Announces Progress Across all Programs within its SGK1 Inhibitor Portfolio
06 Jun 2023 //
PR NEWSWIRE
Thryv Therapeutics to Participate in Piper Sandler Annual Healthcare Conference
17 Nov 2022 //
PRNEWSWIRE